trazodone ER / Generic mfg. - LARVOL DELTA

Bioequivalence test of trazodone sustained-release tablets (ChiCTR) - P=N/A | N=90 | Recruiting | Sponsor: The Affiliated Panyu Central Hospital, Guangzhou Medical University; The Affiliated Panyu Central Hospital, Guangzhou Medical University

New trial • CNS Disorders • Depression • Mood Disorders • Psychiatry

TRAZODONE AND CLINICAL OUTCOMES IN OSA: A NATIONAL REAL-WORLD MATCHED COHORT STUDY (CHEST 2026) - No abstract available

Clinical • Clinical data • Real-world • Real-world evidence • CNS Disorders • Sleep Disorder

Extended-Release Trazodone in Comorbid Major Depressive and Sedative-Hypnotic/Anxiolytic Use Disorders: A Real-World Preliminary Evaluation of Multidimensional Outcomes. (PubMed, J Clin Med) - "Side effects were mild (25.7% at one month) and declined over time. In this uncontrolled preliminary study, extended-release trazodone was associated with significant improvements across multiple symptom domains in MDD+SHA-UD, warranting controlled investigation."

Journal • Real-world evidence • CNS Disorders • Cognitive Disorders • Depression • Insomnia • Major Depressive Disorder • Mood Disorders • Psychiatry • Sleep Disorder

Role of the Amygdala in the Complex Relationship Between Sleep and Anxiety. (PubMed, Int J Mol Sci) - "Trazodone, a serotonin antagonist and reuptake inhibitor (SARI), improves sleep by blocking serotonin receptors and is effective in treating post-traumatic stress disorder (PTSD) related sleep disturbances...At the same time, agomelatine, an antidepressant with anxiolytic properties, improves sleep quality without disrupting REM sleep and treats insomnia associated with various conditions, including alcohol dependence. The aim of this review is to summarize amygdala functions, with a focus on their role in regulating sleep and affective responses. Moreover, it discusses possible therapeutic targets in the amygdala for anxiety and sleep disorders."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Insomnia • Mood Disorders • Post-traumatic Stress Disorder • Psychiatry • Sleep Disorder

De-Stress Pain Management: Rethinking Opioid and Nonopioid Therapies - Program Evaluation Outcomes based on REMS Blueprint Requirements (PAINWeek 2026) - "Appropriate use of buprenorphine/trazodone for sleep disturbances : +30% (329/1,092) [pre: 63% (684/1,092); post: 93% (1,013/1,092)]; differential impact: +38% (195/514) FM-DOs, +23% (114/498) other DOs, +36% (8/22) non-DOs... A total of 2,587 learners engaged with the education. The majority (96%) were physicians, 51% of whom were FM-DOs and 45% were other specialty DOs. A minority (4%) were non-DOs."

Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Sleep Disorder

Psychotropic Polypharmacy in Alzheimer's Disease: A Potentially Inappropriate Medication Perspective in Older Adults. (PubMed, Curr Alzheimer Res) - "This review specifically examines anticholinergic drugs, antipsychotics, benzodiazepines and Z-drugs, tricyclic antidepressants, and select newer antidepressants-including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), mirtazapine, trazodone, and paroxetine-guided by the 2023 American Geriatrics Society (AGS) Beers Criteria®. Current evidence indicates that these medications may contribute to cognitive decline through anticholinergic burden, sedation, and pharmacodynamic interactions with cholinesterase inhibitors, such as donepezil and memantine...This study also summarizes current nonpharmacological strategies and proposes a structured clinical medication review framework. Overall, this review highlights the importance of minimizing inappropriate psychotropic use in AD, prioritizing non-pharmacological interventions, and conducting individualized risk-benefit assessments in clinical practice."

Journal • Alzheimer's Disease • Anesthesia • CNS Disorders • Dementia • Psychiatry

Exploratory prescribing risk profiles and drug drug interaction burden in older adults with depressive episodes. (PubMed, Front Psychiatry) - "Leading major DDI pairs included cardiovascular, carbamazepine-related, and trazodone-related interactions. Database-identified potential DDI burden was substantial among older adults with depressive episodes and was driven mainly by medication load. Anxiety overlap, recurrent sedative-related moderate potential DDIs, and higher-burden prescribing risk profiles highlight the need for structured, regimen-level medication review."

Journal • Cardiovascular • CNS Disorders • Depression • Geriatric Disorders • Mood Disorders • Psychiatry

Effects of Trazodone on Testicular Morphology, Sperm Parameters and Contractility of the Distal Cauda Epididymal Duct in Rats. (PubMed, Basic Clin Pharmacol Toxicol) - "In conclusion, trazodone exhibited significant reproductive effects that may impair male fertility. These findings provide, to our knowledge, the first integrated assessment of trazodone-induced changes in testicular morphology, sperm parameters and epididymal duct contractility."

Journal • Preclinical • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Sexual Disorders

Scleroderma, Stasis, and Sarcina: A Rare Gastric Infection in Systemic Sclerosis (ACG 2026) - "Case Description/ A 70-year-old woman with systemic sclerosis complicated by esophageal aperistalsis, and chronic use of methadone and trazodone presented with progressive dysphagia and reflux...She was treated with amoxicillin-clavulanate, high-dose proton pump inhibitor, and prucalopride as a prokinetic agent...Although ciprofloxacin plus metronidazole is the most commonly reported regimen, no formal treatment guidelines exist. In vitro susceptibility data suggest efficacy of penicillins, fluoroquinolones, macrolides, and tetracyclines. Our use of amoxicillin-clavulanate to avoid QT prolongation risk represents a novel therapeutic approach. This case highlights the importance of evaluating for underlying causes of delayed gastric emptying when S. ventriculi is detected, the variable clinical spectrum of this organism, and the role of individualized antibiotic selection when standard regimens are contraindicated."

Gastrointestinal Disorder • Immunology • Infectious Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

A Fatal Case of Suspected Duloxetine-Induced Acute Liver Failure (ACG 2026) - "She received N-acetylcysteine (NAC), lactulose, fomepizole, antibiotics, and supportive care before transfer to a transplant center...Though ischemic hepatitis, alcohol-associated liver disease, and trazodone hepatotoxicity remained considerations, the marked aminotransferase elevation and hyperacute injury pattern were atypical for isolated alcohol-associated hepatitis. Clinicians should recognize rare but potentially fatal duloxetine-associated hepatotoxicity, particularly in patients with underlying hepatic damage. Early recognition, medication withdrawal, NAC initiation, and rapid transfer to a transplant center are critical in suspected severe DILI."

Clinical • Acute Kidney Injury • Addiction (Opioid and Alcohol) • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Depression • Endocrine Disorders • Genetic Disorders • Hematological Disorders • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Movement Disorders • Nephrology • Pneumonia • Portal Hypertension • Renal Disease • Respiratory Diseases • Thrombocytopenia • Thrombosis

Patient characteristics, treatment patterns and clinical response in patients with treatment resistant depression starting a new treatment in the clinical setting: a multicenter, observational study in Portugal. (PubMed, Front Psychiatry) - "TRD treatments initiated at baseline were varied; the most common treatments initiated or ongoing at baseline were mirtazapine (43.1%), venlafaxine (42.5%), quetiapine (25.5%), and trazodone (20.9%). Outcomes for patients with TRD in real-world clinical practice remain poor, with most patients not responding after 20 weeks of treatment. Treatment heterogeneity highlights a lack of clinical consensus, and the need for novel therapeutics and improved treatment protocols for TRD in real-world clinical practice in Portugal."

Clinical • Journal • Observational data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Sustainable Biochars from Agri-Food Residues for the Selective Removal of Pharmaceuticals: Performance Under Untreated Wastewater Conditions. (PubMed, Molecules) - "In this study, biochars derived from agri-food wastes, including different avocado residues (peel- and seed-derived fractions), olive pits and cherry stones, were evaluated as low-cost and sustainable adsorbents for the removal of the emerging contaminants sulfamethoxazole (SMX), antipyrine (ANT) and trazodone (TRZ) from aqueous solutions...Finally, high removal efficiencies were maintained when applying the selected biochar to real municipal wastewater, demonstrating robustness under complex matrix conditions. Overall, the results highlight the potential of these agri-food waste-derived biochars, including multiple avocado fractions, as sustainable and economically viable adsorbents for quaternary wastewater treatment."

Journal

Comparative Efficacy and Safety of Treatments for Parkinson's Disease With Depression: A Systematic Review and Bayesian Model-Based Network Meta-Analysis. (PubMed, Brain Behav) - "Our findings indicate that selective serotonin reuptake inhibitors (SSRIs), dopamine agonists, and rTMS suggest relative efficacy and an acceptable safety profile in treating PD with depression. However, given the limited evidence for several interventions, these findings should be interpreted cautiously and confirmed in larger, multicenter studies."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

N-(2-(1H-indol-2-yl)ethyl)-2-(1H-indol-3-yl)-N-methylethan-1-amine (CPI-7168): A new 5-HT2A partial agonist and 5-HT2C agonist | Poster Board #1466 (ACS-Fall 2026) - "A broad safety screen analysis of 82 binding and enzyme assays demonstrated activity only at 5-HT and alpha 1A and 1B receptors (the antidepressant trazodone has this dual activity also)...This illustrates the potential use of generative approaches to focus design ideas combined with in vitro and in vivoapproaches which may be novel for OUD research. Future work will focus on characterization of the targets described, improving metabolic stability as well as assessing the efficacy of CPI-7168 in animal models."

Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Real-world safety profile of trazodone: Evidence from FAERS pharmacovigilance data (2004-2024). (PubMed, Australas Psychiatry) - "Additionally, new and clinically significant rare AEs, such as hyper IgE syndrome and acute myopia, were identified.ConclusionsThis study provides valuable data on the AEs of trazodone, particularly its potential reproductive system adverse effects, cardiovascular risks, and other rare events. Our findings lay the foundation for further safety assessments of trazodone."

Adverse events • Journal • Real-world evidence • Cardiovascular • CNS Disorders • Depression • Hematological Disorders • Immunology • Infectious Disease • Insomnia • Major Depressive Disorder • Mood Disorders • Ophthalmology • Primary Immunodeficiency • Psychiatry • Sleep Disorder • Thrombosis

Cenobamate and Trazodone Combination Suppresses Seizures, EEG Alterations, Preserves Neuronal Architecture and Normalizes the BDNF/TrkB Expression in PTZ‑Kindled Mice. (PubMed, Neurochem Res) - "Therefore, we investigated the effect of cenobamate (CNB, 30 mg/kg) and trazodone (TZ, 10 mg/kg), alone and in combination, in PTZ-kindling model, where mice received 11 doses of pentylenetetrazole (PTZ, 40 mg/kg) every other day for three weeks. These parallel findings suggest that positive allosteric GABAA modulation and persistent sodium-current inhibition by CNB, combined with TZ serotonergic modulation, reduce hyperexcitability, pathological neuroplasticity, and glial reactivity. Collectively, TZ + CNB is a promising mechanistically complementary regimen that suppresses seizure progression and associated molecular and neurostructural pathology, which needs further preclinical optimization and translational investigations."

Journal • Preclinical • CNS Disorders • Epilepsy • BDNF • GFAP • NTRK2

Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. (PubMed, Focus (Am Psychiatr Publ)) - "In head-to-head studies, agomelatine, amitriptyline, escitalopram, mirtazapine, paroxetine, venlafaxine, and vortioxetine were more effective than other antidepressants (range of ORs 1·19-1·96), whereas fluoxetine, fluvoxamine, reboxetine, and trazodone were the least efficacious drugs (0·51-0·84). For acceptability, agomelatine, citalopram, escitalopram, fluoxetine, sertraline, and vortioxetine were more tolerable than other antidepressants (range of ORs 0·43-0·77), whereas amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and venlafaxine had the highest dropout rates (1·30-2·32)...These results should serve evidence-based practice and inform patients, physicians, guideline developers, and policy makers on the relative merits of the different antidepressants. National Institute for Health Research Oxford Health Biomedical Research Centre and the Japan Society for the Promotion of Science.Appeared..."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Comparative Efficacy of Interventions for the Prevention and Treatment of Postpartum Depression: A Bayesian Network Meta-analysis. (PubMed, Clin Psychopharmacol Neurosci) - "Based on single small trials, trazodone and diphenhydramine showed statistically superior efficacy to placebo in preventing PPD. Safety considerations in the perinatal and breastfeeding context must be carefully evaluated before these agents are considered in clinical practice."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry

Transient echocardiographic and cardiovascular changes temporally associated with trazodone administration in a geriatric dog. (PubMed, Vet Anaesth Analg) - "Similar cardiovascular findings did not recur after subsequent trazodone dosing under conditions of improved intravascular volume. This case describes transient cardiovascular changes temporally associated with trazodone use in a geriatric dog undergoing preanaesthetic assessment and highlights the potential influence of intravascular volume status on interpretation of cardiovascular findings."

Journal • Anesthesia • Cardiovascular

Probable Serotonin Syndrome Precipitated by the Addition of Trazodone to Lurasidone and Valproic Acid: A Case Report. (PubMed, Sante Ment Que) - "Besides trazodone, the patient was prescribed valproic acid, lurasidone, estradiol, dexlansoprazole and spironolactone. Although most cases of SS associated with trazodone involve selective serotonin reuptake inhibitor antidepressants, this case report suggests that the combination of trazodone, lurasidone and valproic acid can lead to excessive serotoninergic activity via serotonin reuptake inhibition, 5-HT1A partial agonism and increased central serotoninergic neurotransmission. Therefore, clinicians should exercise caution when trazodone is combined with a second-generation antipsychotic and valproic acid."

Journal • CNS Disorders • Insomnia • Movement Disorders • Sleep Disorder

Serotonergic Antidepressant Initiation is Associated with Increased Platelet Inhibition Variability After Lower Extremity Revascularization. (PubMed, J Vasc Surg) - "Serotonergic antidepressant initiation, rather than stable ongoing therapy, was associated with increased instability in ADP-mediated platelet inhibition after lower extremity revascularization. These findings identify the peri-initiation window with implications for medication reconciliation in vascular surgery patients and raise the hypothesis that background P2Y12 regimen consistency may modulate the magnitude of serotonergic medication-induced platelet instability."

Journal • Cardiovascular • CNS Disorders • Depression • Mental Retardation • Peripheral Arterial Disease • Psychiatry

An Emerging Synthetic Opioid in the Drug Supply: A Case of Opioid Overdose with Biological Confirmation of Cychlorphine. (PubMed, J Med Toxicol) - "This rare case of clinical signs of opioid overdose with cychlorphine detected is the first to provide direct evidence linking a non-fatal overdose to cychlorphine exposure. A naloxone responsive opioid toxidrome is described with an opiate and fentanyl negative initial urine drug screen. Advanced analytical techniques were required to identify the presence of cychlorphine."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Psychiatry

Precipitants and clinical features of serotonin syndrome: a systematic review with patient-level analysis of published case reports and series. (PubMed, Eur J Clin Pharmacol) - "Non-suicidal cases of SS during regular prescription were less serious than SS cases associated with intentional overdose. The emerging role of non-antidepressant agents (e.g., several opioids and antiparkinsonian drugs) as potential precipitants support tailored interprofessional medication review in poly-medicated subjects."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Critical care • Movement Disorders • Parkinson's Disease

Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors. (PubMed, Front Psychiatry) - "Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the first-line treatment of ALK-positive metastatic non-small cell lung cancer, frequently associated with psychiatric adverse events. In addition, an overview of the existing literature on the management of psychiatric adverse events (AEs) associated with ALK inhibitors is provided. Based on the evidence presented and the preliminary outcomes observed in the reported case, this study aims to outline a management strategy for lorlatinib-related psychiatric complications."

Adverse events • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Psychiatry • Solid Tumor

Repurposing trazodone for Alzheimer's disease to modulate soluble ST2 levels and alleviate Alzheimer's pathology. (PubMed, Proc Natl Acad Sci U S A) - "Comprehensive molecular profiling of APP/PS1 mouse brains showed that trazodone restored the expression of synaptic proteins critical for synaptic integrity and plasticity. Overall, these findings demonstrate that trazodone is a promising repurposing candidate for AD that targets underlying immune dysfunctions and synaptic impairment."

Journal • Alzheimer's Disease • Amyloidosis • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • IL33